Cerus Corp
NASDAQ:CERS

Watchlist Manager
Cerus Corp Logo
Cerus Corp
NASDAQ:CERS
Watchlist
Price: 1.79 USD 7.19% Market Closed
Market Cap: 332.4m USD
Have any thoughts about
Cerus Corp?
Write Note

Intrinsic Value

The intrinsic value of one CERS stock under the Base Case scenario is 1.55 USD. Compared to the current market price of 1.79 USD, Cerus Corp is Overvalued by 13%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

CERS Intrinsic Value
1.55 USD
Overvaluation 13%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Cerus Corp

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for CERS cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about CERS?
Bearish
Neutral
Bullish

Fundamental Analysis

Economic Moat
Cerus Corp

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about Cerus Corp

Provide an overview of the primary business activities
of Cerus Corp.

What unique competitive advantages
does Cerus Corp hold over its rivals?

What risks and challenges
does Cerus Corp face in the near future?

Has there been any significant insider trading activity
in Cerus Corp recently?

Summarize the latest earnings call
of Cerus Corp.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Cerus Corp.

Provide P/S
for Cerus Corp.

Provide P/E
for Cerus Corp.

Provide P/OCF
for Cerus Corp.

Provide P/FCFE
for Cerus Corp.

Provide P/B
for Cerus Corp.

Provide EV/S
for Cerus Corp.

Provide EV/GP
for Cerus Corp.

Provide EV/EBITDA
for Cerus Corp.

Provide EV/EBIT
for Cerus Corp.

Provide EV/OCF
for Cerus Corp.

Provide EV/FCFF
for Cerus Corp.

Provide EV/IC
for Cerus Corp.

Show me price targets
for Cerus Corp made by professional analysts.

What are the Revenue projections
for Cerus Corp?

How accurate were the past Revenue estimates
for Cerus Corp?

What are the Net Income projections
for Cerus Corp?

How accurate were the past Net Income estimates
for Cerus Corp?

What are the EPS projections
for Cerus Corp?

How accurate were the past EPS estimates
for Cerus Corp?

What are the EBIT projections
for Cerus Corp?

How accurate were the past EBIT estimates
for Cerus Corp?

Compare the revenue forecasts
for Cerus Corp with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Cerus Corp and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Cerus Corp against its competitors.

Analyze the profit margins
(gross, operating, and net) of Cerus Corp compared to its peers.

Compare the P/E ratios
of Cerus Corp against its peers.

Discuss the investment returns and shareholder value creation
comparing Cerus Corp with its peers.

Analyze the financial leverage
of Cerus Corp compared to its main competitors.

Show all profitability ratios
for Cerus Corp.

Provide ROE
for Cerus Corp.

Provide ROA
for Cerus Corp.

Provide ROIC
for Cerus Corp.

Provide ROCE
for Cerus Corp.

Provide Gross Margin
for Cerus Corp.

Provide Operating Margin
for Cerus Corp.

Provide Net Margin
for Cerus Corp.

Provide FCF Margin
for Cerus Corp.

Show all solvency ratios
for Cerus Corp.

Provide D/E Ratio
for Cerus Corp.

Provide D/A Ratio
for Cerus Corp.

Provide Interest Coverage Ratio
for Cerus Corp.

Provide Altman Z-Score Ratio
for Cerus Corp.

Provide Quick Ratio
for Cerus Corp.

Provide Current Ratio
for Cerus Corp.

Provide Cash Ratio
for Cerus Corp.

What is the historical Revenue growth
over the last 5 years for Cerus Corp?

What is the historical Net Income growth
over the last 5 years for Cerus Corp?

What is the current Free Cash Flow
of Cerus Corp?

Discuss the annual earnings per share (EPS)
trend over the past five years for Cerus Corp.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Cerus Corp

Current Assets 140.6m
Cash & Short-Term Investments 75.6m
Receivables 24.4m
Other Current Assets 40.7m
Non-Current Assets 48.9m
PP&E 16.4m
Intangibles 1.3m
Other Non-Current Assets 31.2m
Current Liabilities 54.3m
Accounts Payable 15.9m
Accrued Liabilities 18.1m
Other Current Liabilities 20.3m
Non-Current Liabilities 81.7m
Long-Term Debt 64.8m
Other Non-Current Liabilities 16.9m
Efficiency

Earnings Waterfall
Cerus Corp

Revenue
197.9m USD
Cost of Revenue
-78.1m USD
Gross Profit
119.8m USD
Operating Expenses
-131.6m USD
Operating Income
-11.8m USD
Other Expenses
-7.9m USD
Net Income
-19.7m USD

Free Cash Flow Analysis
Cerus Corp

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

CERS Profitability Score
Profitability Due Diligence

Cerus Corp's profitability score is 30/100. The higher the profitability score, the more profitable the company is.

30/100
Profitability
Score

Cerus Corp's profitability score is 30/100. The higher the profitability score, the more profitable the company is.

CERS Solvency Score
Solvency Due Diligence

Cerus Corp's solvency score is 46/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Negative Net Debt
Long-Term Solvency
Average D/E
46/100
Solvency
Score

Cerus Corp's solvency score is 46/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

CERS Price Targets Summary
Cerus Corp

Wall Street analysts forecast CERS stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for CERS is 3.98 USD with a low forecast of 2.53 USD and a high forecast of 5.25 USD.

Lowest
Price Target
2.53 USD
41% Upside
Average
Price Target
3.98 USD
122% Upside
Highest
Price Target
5.25 USD
193% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for CERS?

Click here to dive deeper.

Dividends

Cerus Corp
does not pay dividends
Shareholder Yield

Current shareholder yield for CERS is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

CERS Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

CERS News

Other Videos

Profile

Cerus Corp Logo
Cerus Corp

Country

United States of America

Industry

Health Care

Market Cap

332.3m USD

Dividend Yield

0%

Description

Cerus Corp. engages in the research, development, and manufacturing of biomedical and surgical products. The company is headquartered in Concord, California and currently employs 294 full-time employees. The company is focused on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, which is based on its technology for controlling biological replication, is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. Its INTERCEPT Blood System is intended for use with blood components and certain of their derivatives, such as plasma, platelets, red blood cells. Its product or product candidates under development includes INTERCEPT Blood System-Platelets, INTERCEPT Blood System-Plasma, INTERCEPT Blood System-Red Blood Cells and INTERCEPT Blood System-Cryoprecipitation. The INTERCEPT Blood System is designed to target and inactivate blood-borne pathogens, such as viruses, bacteria and parasites, as well as potentially harmful white blood cells, while preserving the therapeutic properties of platelet, plasma and red blood cell transfusion products.

Contact

CALIFORNIA
Concord
1220 Concord Ave Ste 600
+19252886000.0
www.cerus.com

IPO

1997-01-31

Employees

294

Officers

President, CEO & Director
Mr. William M. Greenman
VP of Finance & CFO
Mr. Kevin D. Green
Chief Operating Officer
Mr. Vivek K. Jayaraman
Chief Legal Officer & General Counsel
Ms. Chrystal Jensen
Chief Medical Officer
Dr. Richard J. Benjamin MBChB, Ph.D.
Co-Founder & Chief Scientific Officer
Dr. Laurence M. Corash M.D.
Show More
Senior Director of Investor Relations
Mr. Matthew M. Notarianni
Vice President of Global Marketing
Lainie Corten
Chief Human Resources Officer
Ms. Alicia Goodman
Senior Vice President of Regulatory Affairs, Quality & Clinical
Ms. Carol M. Moore
Show Less

See Also

Discover More
What is the Intrinsic Value of one CERS stock?

The intrinsic value of one CERS stock under the Base Case scenario is 1.55 USD.

Is CERS stock undervalued or overvalued?

Compared to the current market price of 1.79 USD, Cerus Corp is Overvalued by 13%.

Back to Top